This case is the first to confirm that ACTL cellular immunotherapy has significant efficacy in patients with advanced lung adenocarcinoma who have EGFR-TKI resistance with unknown mechanisms, and can realize the functional reversal of the immune microenvironment from a “cold tumor” to a “hot tumor” through reshaping it. The gene discussed is EGFR; the disease is lung adenocarcinoma.